Evidence map›Paper›PMID 38835954›Full record

ArticleClinical & translational immunology2024

Characterisation of circulating tumor-associated and immune cells in patients with advanced-stage non-small cell lung cancer.

Vahid Yaghoubi Naei, Ekaterina Ivanova, William Mullally, Connor G O'Leary, Rahul Ladwa, Ken O'Byrne, Majid E Warkiani, Arutha Kulasinghe

Abstract read
In one paragraph

Article in Clinical & translational immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vahid Yaghoubi NaeiSchool of Biomedical Engineering University of Technology Sydney Sydney NSW Australia.
Ekaterina IvanovaCancer and Ageing Research Program, Centre for Genomics and Personalised Health Queensland University of Technology Woolloongabba QLD Australia.
William MullallyThe Princess Alexandra Hospital Brisbane QLD Australia.
Connor G O'LearyThe Princess Alexandra Hospital Brisbane QLD Australia.
Rahul LadwaFrazer Institute, Faculty of Medicine The University of Queensland Brisbane QLD Australia.
Ken O'ByrneThe Princess Alexandra Hospital Brisbane QLD Australia.
Majid E WarkianiSchool of Biomedical Engineering University of Technology Sydney Sydney NSW Australia.
Arutha KulasingheFrazer Institute, Faculty of Medicine The University of Queensland Brisbane QLD Australia.ORCID https://orcid.org/0000-0003-3224-7350

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Globally, non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer and the leading cause of cancer-related deaths. Tumor-associated circulating cells in NSCLC can have a wide variety of morphological and phenotypic characteristics, including epithelial, immunological or hybrid subtypes. The distinctive characteristics and potential clinical significance of these cells in patients with NSCLC are explored in this study. Methods: We utilised a spiral microfluidic device to enrich large cells and cell aggregates from the peripheral blood samples of NSCLC patients. These cells were characterised through high-resolution immunofluorescent imaging and statistical analysis, correlating findings with clinical information from our patient cohort. Results: We have identified varied populations of heterotypic circulating tumor cell clusters with differing immune cell composition that included a distinct class of atypical tumor-associated macrophages that exhibits unique morphology and cell size. This subtype's prevalence is positively correlated with the tumor stage, progression and metastasis. Conclusions: Our study reveals a heterogeneous landscape of circulating tumor cells and their clusters, underscoring the complexity of NSCLC pathobiology. The identification of a unique subtype of atypical tumor-associatedmacrophages that simultaneously express both tumor and immune markers and whose presence correlates with late disease stages, poor clinical outcomes and metastatic risk infers  the potential of these cells as biomarkers for NSCLC staging and prognosis. Future studies should focus on the role of these cells in the tumor microenvironment and their potential as therapeutic targets. Additionally, longitudinal studies tracking these cell types through disease progression could provide further insights into their roles in NSCLC evolution and response to treatment.

Indexed as

circulating tumor cell clusterscirculating tumor cellsmetastasismicrofluidicsNSCLCtumor associated macrophages

Identifiers

PMID38835954
PMCPMC11147668

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.